Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2026)

Barinthus Biotherapeutics filings provide 6 years of Return on Capital Employed readings, the most recent being 67.38% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed fell 1590.0% to 67.38% in Q1 2026 year-over-year; TTM through Mar 2026 was 67.38%, a 1590.0% decrease, with the full-year FY2025 number at 59.18%, down 1960.0% from a year prior.
  • Return on Capital Employed hit 67.38% in Q1 2026 for Barinthus Biotherapeutics, up from 75.33% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 1.67% in Q3 2022 to a low of 75.87% in Q3 2025.
  • Median Return on Capital Employed over the past 5 years was 40.16% (2024), compared with a mean of 36.99%.
  • Biggest five-year swings in Return on Capital Employed: soared 1684bps in 2022 and later tumbled -4223bps in 2023.
  • Barinthus Biotherapeutics' Return on Capital Employed stood at 1.52% in 2022, then crashed by -2529bps to 40.03% in 2023, then decreased by -7bps to 42.79% in 2024, then plummeted by -76bps to 75.33% in 2025, then increased by 11bps to 67.38% in 2026.
  • The last three reported values for Return on Capital Employed were 67.38% (Q1 2026), 75.33% (Q4 2025), and 75.87% (Q3 2025) per Business Quant data.